Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Adaptive Biotechnologies CorpTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Ginkgo Bioworks Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Ginkgo Bioworks Holdings Inc trades at $7.58 (market cap $505.73M). The key difference: Adaptive Biotechnologies Corp is far larger — about 8× Ginkgo Bioworks Holdings Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.

ADPTDNA
Market Cap
$4.04B$505.73M
Sector
HealthHealth
52-Week High
$25.45$16.14
52-Week Low
$12.30$5.48
Enterprise Value
$4.10B$607.68M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.

Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.

Ginkgo Bioworks Holdings Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA